A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 11, 2013

Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients

CROI 2013Interim 24-week results from a Phase III study comparing the investigatory dolutegravir to raltegravir among HIV-positive individuals who have experienced treatment failure suggest that dolutegravir is superior at suppressing virus. ViiV Healthcare announced these midway results from their 48-week, double-blind, double-dummy Phase III SAILING study at the 20th annual Conference of Retroviruses and Opportunistic Infections (CROI) in Atlanta.  

At the outset, the study’s 715 participants had resistance to at least two classes of antiretrovirals (ARVs). They also had replicating virus, a median baseline viral load of 63,000 and a median baseline CD4 count of 200. The participants were divided evenly into two study groups: One received once-daily dolutegravir and the other twice-daily raltegravir, both with a background regimen of no more than two other ARVs that the investigators selected.

At week 24 of the study, 79 percent of those taking dolutegravir achieved a suppressed viral load, compared with 70 percent of those on raltegravir. This difference was statistically significant, meaning that it was too great to have occurred by chance. At the same point, 15 percent of those on dolutegravir and 24 percent of those taking raltegravir had a virologic nonresponse. Two of those on the dolutegravir regimen failed therapy, compared with 10 of those taking raltegravir.

The tolerability of the two drugs was about even. At the 24-week mark, 2 percent of the participants taking dolutegravir discontinued because of adverse events, compared with 4 percent of those on raltegravir. Drug-related adverse events occurred in 20 percent of those on dolutegravir and 23 percent of those taking raltegravir. The most common adverse events were diarrhea and upper respiratory tract infection.

To read the ViiV release, click here.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: dolutegravir, raltegravir, HIV, salvage, phase III, SAILING, 20th annual Conference of Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dversescott
    Baltimore
    Maryland


    mtaj0818
    Washington
    DC


    usuallyhappy
    Palm Springs
    California


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.